Multiple combinations of melanocytic and vascular endothelial markers enhance the detection rate of lymphovascular invasion in cutaneous melanoma
- PMID: 32935876
- DOI: 10.1111/cup.13874
Multiple combinations of melanocytic and vascular endothelial markers enhance the detection rate of lymphovascular invasion in cutaneous melanoma
Abstract
Background: Lymphovascular invasion (LVI) is believed to be the mechanism by which melanoma cells can disseminate to regional lymph nodes and distant sites and may be predictive of adverse outcome. Lymphovascular invasion often difficult to detect on hematoxylin-eosin (HE) stained sections, are readily identified with dual immunohistochemistry (IHC) for melanocytic and vascular markers.
Methods: A total of 100 primary cutaneous malignant melanoma cases that had a Breslow thickness of 1-4 mm and lacked LVI by conventional HE assessment were included. We compared the LVI detection rates of double staining for CD31/S100 and CD34/S100, and D2-40/S100, and examined the association of LVI with clinical outcomes.
Results: The dual immunohistochemical positivity for CD31/S100, CD34/S100, and D2-40/S100 were 40(40%), 17(17%) and 35(35%), respectively. On multivariate analysis, LVI was an independent predictor of SLN status. Multivariate analysis revealed that LVI and male gender were independent risk factors for overall survival.
Conclusions: The recognition of LVI is improved by dual IHC and predicts SLN metastasis. The detection of LVI using dual IHC, especially by a combination of CD31/S100 and D2-40/S100 is a useful step that inclusion should be recommended in basic evaluation parameters for cutaneous melanoma.
Keywords: dual immunohistochemistry; lymphovascular invasion; melanoma; sentinel lymph node.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Similar articles
-
Prognostic Implication of Lymphovascular Invasion Detected by Double Immunostaining for D2-40 and MITF1 in Primary Cutaneous Melanoma.Am J Dermatopathol. 2016 Jul;38(7):484-91. doi: 10.1097/DAD.0000000000000453. Am J Dermatopathol. 2016. PMID: 26675354
-
Clinical relevance of detection of lymphovascular invasion in primary melanoma using endothelial markers D2-40 and CD34.Am J Surg Pathol. 2011 Oct;35(10):1441-9. doi: 10.1097/PAS.0b013e31822573f5. Am J Surg Pathol. 2011. PMID: 21881483 Free PMC article.
-
Lymphatic invasion detected by D2-40/S-100 dual immunohistochemistry does not predict sentinel lymph node status in melanoma.J Am Acad Dermatol. 2009 Nov;61(5):819-28. doi: 10.1016/j.jaad.2009.04.026. J Am Acad Dermatol. 2009. PMID: 19836642
-
Three Types of Nodal Melanocytic Nevi in Sentinel Lymph Nodes of Patients With Melanoma: Pitfalls, Immunohistochemistry, and a Review of the Literature.Am J Dermatopathol. 2020 Oct;42(10):739-744. doi: 10.1097/DAD.0000000000001645. Am J Dermatopathol. 2020. PMID: 32271206 Review.
-
False-positive cells in sentinel lymph nodes.Semin Diagn Pathol. 2008 May;25(2):116-9. doi: 10.1053/j.semdp.2008.03.001. Semin Diagn Pathol. 2008. PMID: 18697715 Review.
Cited by
-
Immunohistochemistry for Skin Cancers: New Insights into Diagnosis and Treatment of Melanoma.Cancers (Basel). 2025 May 25;17(11):1769. doi: 10.3390/cancers17111769. Cancers (Basel). 2025. PMID: 40507250 Free PMC article. Review.
References
REFERENCES
-
- Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19(16):3622-3634.
-
- Balch CM, Cascinelli N. Sentinel-node biopsy in melanoma. N Engl J Med. 2006;355(13):1370-1371.
-
- Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472-492.
-
- Egger ME, Gilbert JE, Burton AL, et al. Lymphovascular invasion as a prognostic factor in melanoma. Am Surg. 2011;77(8):992-997.
-
- Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355(13):1307-1317.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous